







Prescription drug misuse and opioid overdose death have increased significantly in recent years. Many states have implemented Prescription Drug Monitoring Programs (PDMPs) as a means to improve prescribing practices and mediate the ongoing opioid crisis in the United States (US). This comprehensive literature review examines the current structure of state-run PDMPs, and legislation surrounding them. More specifically, the Pennsylvania PDMP is examined. Limitations and barriers to use of PDMPs are explored. Recommendations are provided for improving current state-run PDMPs, and a proposal is made for the development of a national-level prescription drug monitoring database.




 TOC \o "2-3" \h \z \t "Heading 1,1,Appendix,1,Appendix Title,1,Heading,1" 1.0	INTRODUCTION	1
2.0	A Brief History of opioid USe in the united states	2
2.1	NEUROPHARMACOLOGY OF OPIOID DRUGS	3
2.2	OPIOID DRUG FORMULATIONS AND PAIN MANAGEMENT	5
2.3	opioids and substance use disorder	7
2.4	Chronic Illness and Opioids	9
2.5	Aberrant Drug-Related Behavior	11
2.6	Functional and Health Consequences of Opioid Use Disorder	12
3.0	Overveiw of the Current And Ongoing Opioid Crisis In the United STates	14
3.1	Impact of the Opioid Crisis in the STate of Pennsylvania				16
4.0	Overview of State-Run prescription drug monitoring programs	18
4.1	the Pennsylvania Prescription Drug Monitoring Program	20
4.2	Impact of Prescription Drug Monitoring Programs	21
4.3	Limitations on Monitoring programs in their current state		23
5.0	recommendations for improving prescription monitoring programs and preventing substance use disorder	25
5.1	Public Health Implications of a National Level Prescription Monitoring Database	26
5.1.1	Potential Impact on Infectious Disease Transmission	27
5.1.2	Recommendations for Improving Prescription Drug Monitoring Program Use and Substance Use Disorder Treatment	29
5.1.3	Conclusions	31
APPENDIX: U.S. DRUG ENFORCEMENT ADMINISTRATION DEFINITIONS OF DRUG SCHEDULES	33
bibliography	35
List of tables
 TOC \h \z \c "Table" Table 1. Classification of Opioids by Receptor Effect	4
Table 2. Opioid Receptors by Function	5
Table 3. Opioids by Half-Life and Morphine Milligram Equivalent	6




I would like to acknowledge several individuals for their contributions to this work, and to my professional and personal development during my time enrolled in the University of Pittsburgh Graduate School of Public Health.
First, I would like to thank my committee chair and academic advisor, Dr. Frank, for her support, guidance, and for persistently challenging me to achieve my fullest potential through my coursework in the Department of Infectious Diseases and Microbiology, and throughout the planning and development of this essay.
I would also like to thank Dr. Terry for helping inspire me to pursue a career in public health during my undergraduate coursework at Pitt, for her mentorship throughout my graduate career, and for serving on my committee as a reader and reviewer for this essay.    
I would like to thank my father, Tim, for his love, support, and guidance through my graduate and professional development, and for serving informally to review each draft before presentation to my committee.







Prescription misuse in the United States has been increasingly prevalent in the past since the early 2000. An analysis of data from the National Health and Nutrition Examination Survey (NHNES) found about an 8% increase in adults reporting misusing prescriptions of any kind between 2000 and 2012 (). Currently, forty-nine states (all except for Missouri) have implemented prescription drug monitoring programs, called PDMPs or PMPs for short, as a means to combat the ongoing opioid crisis by providing clinicians with a tool to aid them in prescribing, managing care, and identifying and treating individuals with substance use disorders (SUD).
	The following essay provides a brief history of medical opioid use in the United States, a history and overview of the current and ongoing opioid crisis, and a timely analysis of state-run PDMPs. More specifically, a comprehensive literature review surrounding PDMPs was conducted to provide an in-depth analysis of PDMP structure (database characteristics, laws surrounding use, etc.), impact on public health, and limitations in the current state.
	Lastly, a proposal is made for a national level prescription monitoring database as a means to address the limitations of current state-run PDMPs, as well as recommendations for improving opioid prescription dispensing. Suggestions are made regarding the impact the proposed national prescription drug monitoring program could have on the opioid crisis and public health, including the potential impact on infectious disease transmission.
2.0 	A Brief History of opioid USe in the united states
The use of opium and opium derivatives for their analgesic and sedative effects has been well documented throughout history, with the earliest known references dating back to 3400 B.C. in Mesopotamia (). Prominent medical usage of these derivatives in the United States (U.S) began with the isolation of morphine in the early 1800s. Morphine was used to treat a variety of ailments, most notably, as an analgesic for soldiers who sustained battle injuries and those undergoing emergency surgeries during the American Civil War, resulting in a large number of soldiers developing addictions to morphine (). This condition was eventually named “Soldier’s Disease” due to its lasting prevalence beyond the conclusion of the war (). 
Recognizing the high potential for addiction, alternatives to morphine were sought that retained the therapeutic effects of the drug while minimizing the risk for dependence.  This approach has led to subsequent development of opium derivatives and synthetic drugs.  Furthermore, it has provided the impetus for the development and enactment of ordinance, laws and other legislation at the state and federal levels. 
In addition to the creation of agencies to evaluate the safety and proper dosing of drugs like the Food and Drug Administration (FDA), many states have developed databases for monitoring the prescribing and dispensing of controlled substances and prescription drugs. 
2.1	NEUROPHARMACOLOGY OF OPIOID DRUGS
The term opioid is generally used to encompass all naturally-derived and synthetic compounds that act on opioid receptors in the central and peripheral nervous systems. Opioids, like other psychotropic drugs, can be categorized according to the different effects they have on receptors such as the following:

Agonists- “A chemical substance capable of combining with a specific receptor on a cell and initiating the same reaction or activity typically produced by the binding endogenous substance” (). 

Partial Agonists- Substances that bind to and stimulate receptors to produce a biological response, however, have lesser efficacy in comparison to agonists. When present with full agonists, partial agonists can act as competitive antagonists, binding to the same receptors and producing a diminished overall response ().

Antagonists- “A chemical that acts within the body to reduce the physiological activity of another chemical substance (such as an opiate); especially: one that opposes the action on the nervous system of a drug or a substance occurring naturally in the body by combining with and blocking its nervous receptor”(). 

Generally, opioid receptor agonists and synthetic agonists are used medically to treat chronic and acute pain for their ability to affect analgesia. These compounds are also the most frequently misused type of opioids, as they induce euphoria as well. Partial opioid receptor agonists have shown some utility in treating chronic pain but are primarily used medically in treating opioid use disorders by managing withdrawal symptoms. Opioid receptor antagonists are primarily used medically to prevent opioid overdose for their ability to block the effect agonists. Table 1 below lists common opioid compounds classified by the effect they have on opioid receptors.














Although recent evidence suggests that subtypes may exist, it is generally accepted that there are three types of opioid receptors where drugs can produce effects throughout the central and peripheral nervous systems (): DOP (delta opioid receptor), KOP (kappa opioid receptor), and MOP (mu opioid receptor).  Evidence suggests that MOP activation by agonist compounds, such as in the case of morphine, is the primary mechanism by which opioid-induced analgesia is produced (). Table 2 below provides more detail on the functions of each opioid receptor class.  

Table 2. Opioid Receptors by Function
Opioid Receptor Class	Function
µ1 (Mu subtype 1)	Confusion, dizziness, euphoria, nausea, supraspinal analgesia
µ2 (Mu subtype 2)	Cardiovascular and gastrointestinal effects, miosis, respiratory depression
δ (Delta)	Cardiovascular depression, decreased brain and myocardial oxygen demand, spinal analgesia
κ (Kappa)	Dysphoria, feedback inhibition of endorphin system, psychomimetic effects, spinal analgesia
 Source: ()
2.2	OPIOID DRUG FORMULATIONS AND PAIN MANAGEMENT
Important to understanding opioid-induced analgesia and euphoria are the pharmacokinetic properties of different opioid compounds. Fentanyl, for example, acts as a MOP receptor agonist like morphine however; is highly lipid soluble and thus the onset and peak of effects are much more rapid. Opioid drugs are generally classified as short-acting or long-acting based on these properties and the duration of their effects (). Formulation of the drug itself is also an important factor to consider when trying to appropriately manage pain, as formulations can be altered to affect the release of the drug, and therefore, alter drug plasma concentration and duration of its effects. Table 3 below provides a list of common opioids, their biological half-life, and oral morphine milligram equivalent (MME). Drugs with a greater biological half-life are considered longer-acting. 

Table 3. Opioids by Half-Life and Morphine Milligram Equivalent
Opioid	Biological Half-Life	Oral Morphine  Milligram Equivalent
Buprenorphine	24 – 60 h	10
Butorphanol	6 – 10 h	7
Codeine	2.5 – 3 h	0.15
Dihydrocodeine	4 h	0.25
Fentanyl	10 – 20 min	0.13
Heroin	2 – 3 min	1 – 2
Hydrocodone	3.8 h	1
Hydromorphone	2 – 3 h	4
Merperidine	3 h	0.1
Methadone	Variable with dose	4-12 (variable with dose)
Morphine	2 – 3 h	1
Nalbuphine	3 – 6 h	1
Naloxone	1 – 1.5 h	N/A
Naltrexone	4 h	N/A
Oxycodone	3 – 4.5 h	1.5
Oxymorphone	1.3 h	3
Pentazocine	2 – 3 h	0.37
Propoxyphene	6 – 12 h	0.16
Tramadol	5.5 – 7 h	0.1
 Sources: (; )
2.3	opioids and substance use disorder
Addiction has long been a significant public health problem in the United States and worldwide, resulting in enormous suffering and a wide range of negative health, social, occupational, and economic effects upon individuals, their family members, communities, and nations. Addictive disorders in the United States are common and have had a significant impact on illness, mortality rates, and quality of life in many communities, as has been extensively documented in recent American news media coverage. 
Substance use disorders are frequently comorbid with other mental disorders. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) cites the onset of anxiety disorders, depressive disorders, sleep disorders, sexual dysfunction, and delirium as diagnoses associated with opioid intoxication and/or withdrawal (). Other risks associated with substance use include interpersonal aggression and violence, risky sexual behavior, sexual violence, psychotic disorders, and antisocial personality disorder ().
As found by the 2016 Substance Abuse and Mental Health Services Administration (SAMSHA) National Survey, 18.5% of adults age 18 or older with a mental illness diagnosis had used substances within the past year. According to the National Institute on Drug Abuse, individuals addicted to drugs are twice as likely to also suffer from mood and anxiety disorders (, ). A recent study on prescription opioid use and mental disorders found that the 16% of American who have mental disorders receive more than half of U.S. opioid prescriptions  ADDIN EN.CITE ().
As described in the diagnostic criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, substance use disorders include “A cluster of cognitive, behavioral, and physiological symptoms,” and an individual with a substance use disorder persists in using the substance “despite significant substance-related problems” (). The DSM-5 opioid-related disorders include Opioid Use Disorder, Opioid Intoxication, Opioid Withdrawal, and “other and unspecified opioid-related disorders”. The DSM-5 criteria for Opioid Use Disorder include a “problematic pattern of opioid use leading to clinically significant impairment or distress” over a one year period, as reflected by two or more of the following: using opioids in larger amounts or for longer than intended, trying unsuccessfully to limit or stop use, spending significant time  obtaining, using,  or recovering from use, cravings, failing to fulfill major role obligations, continuing use despite significant interpersonal problems related to substance use, giving up important activities, using of opioids in situations that are physically dangerous, using despite awareness of physical or psychological problems caused by the substance, and experiencing tolerance and/or withdrawal ().
A number of factors have been identified as important aspects of the etiology of substance use disorders. These include genetic inherited vulnerabilities, the functioning of brain reward and stress circuits, learning, modeling, and life events, and cognitive influences ().  It is estimated that half of the risk for addiction is genetic, with genes affecting the extent of reward experienced when using substances or engaging in addictive behaviors and the way the body processes substances (). 
Many researchers have described multiple systemic influences on substance use and the development of addictive disorders. Pihl and Shakra (2015) described influences on addiction at the levels of society, the peer group, the family, and the individual. Societal influences include cultural norms and values regarding drug use, laws and regulations, social consequences of drug use, cultural influences upon expectations regarding the impact of substance use, modeling of substance use (including in media), and the impact of poverty, crime, characteristics of an individual’s residential circumstances, among other social factors (). Peer and family influences are extremely significant in the shaping of values, exposure to modeling, and social learning regarding substance use. Peer factors in substance use include the impact of peers on an individual’s emotional distress, attitudes about oneself, and self-esteem (). Individual factors in substance use include the individual’s history of exposure to stress and trauma, the individual’s emotional functioning and need for escape from emotional distress, which may become a vulnerability to “self-medicate” through substance use, and personality traits such as neuroticism (a proneness to anxiety and negative emotions) and proneness to disinhibition (). 
2.4	Chronic Illness and Opioids
Pain and sleep are common problems and have been associated with opioid use. Almost 50 million American adults suffer from significant chronic pain  ADDIN EN.CITE (). An investigation into factors associated with long-term opioid use among opioid naïve patients conducted by Shah, Hayes, and Martin (2017) indicated, as expected, that people with chronic pain have the highest probability of continued opioid use. Initial prescriptions of Tramadol or long-acting opioids were associated with increased likelihood of long-term use. The authors found that the strongest predictor of continued opioid use was the length of the first prescription, i.e., increased number of days of first prescription predicted longer opioid use  ADDIN EN.CITE ().  In a large cross-sectional study conducted in Florida, 25% of adults reported insomnia and over 50% reported use of opioids; the authors found that insomnia was 42% more likely among prescription opioid users ().
For some, chronic pain stems from a traumatic event, such as a physical or sexual assault, or a motor vehicle accident. Under these circumstances the person may experience both chronic pain and Post Traumatic Stress Disorder (PTSD). The person in pain may not even realize the connection between their pain and a traumatic event. According to the U.S. Department of Veterans Affairs National Center for PTSD, approximately 15% to 35% of patients with chronic pain also have PTSD (). Only 2% of people who do not have chronic pain have PTSD. One study found that 51% of patients with chronic low back pain had PTSD symptoms  (; ). For people with chronic pain, the pain may serve as a reminder of the traumatic event, which may exacerbate PTSD. Survivors of physical, psychological, or sexual abuse tend to be more at risk for developing certain types of chronic pain later in their lives.
The relationship between trauma, trauma-related physical and emotional symptoms, and opioid use have been a focus of increased concern in recent years. In a large-scale study examining the relationship between baseline PTSD and subsequent development of opioid use disorder, baseline PTSD was found to significantly increase the risk of development of opioid use disorder after exposure to opioid medication  ADDIN EN.CITE ().
The issue of the trauma-PTSD-pain-opioid relationship is particularly concerning in military Veteran treatment populations. In a retrospective cohort study of more than 141,000 Iraq and Afghanistan Veterans who received a non-cancer-related pain diagnosis within the Veterans Affairs Health Care System between 10/01/2005 and 12/31/2010, Seal, et. al (2012) found the following: 
•	Veterans with PTSD and/or other mental health diagnoses were significantly more likely to receive opioids for pain diagnoses, compared to veterans without mental health disorders.
•	Compared to those without mental health diagnoses, Veterans with PTSD were more likely to receive higher-dose opioids, receive 2 or more opioids concurrently, receive sedative hypnotics concurrently, or obtain early opioid refills.
•	Receiving prescription opioids was associated with an increased risk of adverse clinical outcomes for all Veterans, and adverse outcomes were most pronounced in veterans with PTSD.

It has become increasingly clear that opioid use disorder is related to a number of frequently occurring medical and psychiatric co-morbidities, including pain disorders, insomnia, and trauma-related mental disorders. Veterans with PTSD appear to be particularly vulnerable to adverse consequences from opioid treatment  ADDIN EN.CITE ().
2.5	Aberrant Drug-Related Behavior 
Additional consequences of opioid use disorder include the diversion of opioid analgesics for nonmedical use and the initiation of nonmedical use among other individuals  ADDIN EN.CITE (). “Aberrant Drug-Related Behaviors” (ADRB) which may occur in chronic opioid use include frequently losing/misplacing opioid prescriptions, requesting early refills, using others’ medication, stealing medication, forging prescriptions, “doctor shopping,” co-occurring use of alcohol and/or illicit substances, patient resistance to changes in treatment. Despite side effects, adverse events or lack of benefit from treatment, altering the route of delivery, unintended emotional/psychic effects of the medication, dose, hoarding medication, and aggressively complaining about need for medication ADRBs often represent transition to an opioid use disorder, and may reflect the presence of significant emotional distress, antisocial behavior, or inadequate pain control (). 
In a cross-sectional study of nearly 300 indigent HIV-infected adults conducted by Hansen, Penko, Guzman, et. al (2011), more than 91.2% of the study participants reported pain during the previous week, with 53.7% reporting severe pain.; 69.2% met criteria for a history of stimulant (e.g., amphetamine or cocaine) or opioid use disorder (DSM-IV diagnostic criteria were used)  ADDIN EN.CITE (). The authors found that 37.4% had a history of aberrant drug-related behaviors (with opioids) within the 90-day period prior to the study interview, with 18.5% having a history of “major” aberrant drug-related behaviors.
2.6	Functional and Health Consequences of Opioid Use Disorder
In addition to overdose-related deaths, mortality associated with Opioid Use Disorder is attributable to accidents, violence, and HIV/AIDS and other medical conditions. Children born to women with Opioid Use Disorder may suffer from physiological dependence on opioids and withdrawal symptoms (called Neonatal Abstinence Syndrome or NAS for short), as well as low birth weight and related complications (). The incidence rate of NAS in the U.S. has increased greatly since the early 2000’s as a result of the increasing prevalence of opioid use. Two recent analyses of data from national-level databases found that the incidence of NAS increased from 1.2 cases per 1,000 hospital births in the year 2000, to 5.8 per 1,000 by 2012- about a 400% increase  ADDIN EN.CITE (; ). The analysis conducted by Ko et al. (2016) also found that the mean hospital stay for infants with NAS was around 16.9 days with a mean hospital charge of $66,700, compared to 2.1 days and $3,500 for full-term infants born without any complications.
In a study of the impact on life expectancy of drug-poisoning- deaths in the U.S. during the period 2000 to 2015, while overall life expectancy increased (though it decreased from 2014 to 2015), drug-poisoning related deaths were found to decrease life expectancy by 0.28 years (). The authors noted that this finding may be a significant underestimation, as death certificates have historically not accurately recorded information in drug-poisoning related deaths (e.g., the specific drug involved).
3.0 	Overveiw of the Current And Ongoing Opioid Crisis In the United STates
The 2015 National Survey on Drug Use and Health  ADDIN EN.CITE () was distributed to over 72,000 noninstitutionalized adult civilians, and completed responses were obtained from more than 51,000 participants. The survey data revealed that 37.8% of the responders used prescription opioids in 2015, 4.7% acknowledged misusing them, and 0.8% had a use disorder (including misuse and prescription opioid use disorder). The leading reported reason for opioid use was pain relief. Patterns of misuse included use opioids without a prescription (59.9% of misusers) and obtaining prescription opioids from others (40.8% of misusers) i.e., family members or friends. The authors found that prescription opioid misuse and opioid use disorders were clearly associated with low socioeconomic status, unemployment, lack of health insurance, and mental health conditions  ADDIN EN.CITE ().
The 2016 SAMSHA Key Substance Use and Mental Health Indicators in the United States: Results from the National Survey on Drug Use and Health report found that 28.6 million Americans age 12 or older acknowledged using an illicit substance within 30 days prior to the survey, approximately 10.6% of the population. The main substances used illicitly were prescription pain medications and cannabis. The survey estimated that there are over 3.3 million active misusers of prescription pain medications. Additionally, an estimated 948,000 Americans age 12 or older used heroin in the past year. Of those, an estimated 641,000 both misused prescription pain medications and used heroin. According to the survey the most commonly misused pain medications were (in descending order) Hydrocodone, Oxycodone, Codeine, Tramadol, Buprenorphine, Morphine, Methadone, and Fentanyl. The survey also assessed reasons for pain reliever misuse. While pain relief was the most common expressed reason (62.3%) others included “feel good or get high” (12.9%), “relax or relieve tension” (10.8%), “help with feelings or emotions” (3.9%), “help with sleep” (3.3%), and “experiment or see what it’s like” (3.0%) (). 
The relationship between prescription opioid use and progression to injection drug use was described by Al Tayyib, Koestler, & Riggs (2017), who found that 32% of a sample of injection drug users reported prescription opioid use disorder prior to injection drug use.  Prescription opioid use disorder prior to initiation of injection drug use was found to be associated with increased risk of overdose  ADDIN EN.CITE (; ). Al Tayyib, Koestler, & Riggs (2017) noted a 1.55-fold increase in the risk of an overdose during the previous 12 months among those who had prescription opioid use disorders prior to beginning injection drug use. As the authors described, the pattern of prescription opioid use disorder prior to injection drug use likely represents a high-risk profile for injection drug users.
The current United States opioid epidemic has been associated with a significant increase in deaths from overdoses. In 2014, 28,000 Americans died from overdoses involving opioids.  In 2015, more than 33,000 died from opioid-related overdoses (). According to the Centers for Disease Control and Prevention (CDC) “deaths from drug overdose are up among both men and women, all races, and adults of nearly all ages,” and “more than three out of five drug overdose deaths involve an opioid” (). In a recent comprehensive review of the opioid epidemic, Manchikanti et al. stated that opioids are “now responsible for more deaths than the number of deaths from both suicide and motor vehicle crashes, or deaths from cocaine and heroin combined,” and that “40% of deaths occur in individuals abusing the drugs obtained through multiple prescriptions, doctor shopping, and drug diversion” (). As noted by Kolodny, et al. (2015), “U.S. consumption of hydrocodone more than doubled and consumption of oxycodone increased by nearly 500%” during the period 1999 to 2011. Over the same period, the overdose death rate associated with opioids “nearly quadrupled”  ADDIN EN.CITE ().
Beyond the tragic loss of life, opioid misuse has significant economic and societal impacts as well, elevating costs relating to the criminal justice system, healthcare and emergency medical services, and lost productivity among those with opioid disorders (). Estimates of the total economic burden of opioid-related substance use disorder and overdose reach as high as $400 billion (; ).
3.1	Impact of the Opioid Crisis in the STate of Pennsylvania
Recent reports by the United States Drug Enforcement Administration have found that the state of Pennsylvania currently has one of the highest rates of overdose in the United States, with around 36.5 overdose deaths per 100,000 people occurring in 2016.  This was significantly higher than the previous year (26.7 per 100,000 in 2015) with the national average of 16.3 per 100,000 in 2015 (, ). In Pennsylvania, a total of 4,642 drug-related overdose deaths were reported in 2016 compared to 3,383 in 2015. Of those 4,642 overdose deaths in 2016, 85% were found to be opioid-related, with fentanyl and fentanyl-related substances identified in 66.5% of these cases- 52% of all cases (, ). 
4.0 	Overview of State-Run prescription drug monitoring programs
According to the National Alliance for Model State Drug Laws (NAMSDL), as of May, 2016, all states except Missouri and the District of Columbia have operational prescription drug monitoring programs (). The District of Columbia had enacted PMDP legislation, but the program was not yet in operation at this time.  Per the NAMSDL 2016 summary, state PMDPs varied significantly in administrative and clinical practice aspects, including the following:
Agency Administering the Program 
-	Health Departments, Boards of Pharmacy, or single state Authority (36 state programs); 
-	Professional Licensing Boards (5 state programs); 
-	Law Enforcement agencies (4 state programs); 
-	Board of Pharmacy in conjunction with another agency (2 state programs); or 
-	Department of Consumer Protection/Division of Consumer Affairs (2 state programs). 
Notification of Consumers that Their PDMP Information May Be Accessed or Reported   
-	Required by 11 states.
Use of an Advisory Committee, Task Force, or Working Group 
-	Required by 34 states.

Reports to State Legislature 
-	Required by 26 states.
Data Collection Interval 
-	“Real time,” (1 state program); 
-	“Real time/24 hours,” (3 state programs); 
-	“Daily/24 hours/1 business day,” (24 state programs); 
-	“3 days/72 hours,” (5 state programs); 
-	“Weekly/7 days,” (15 state programs); or
-	“Monthly,” (1 state program)
Interstate Sharing of Prescription Monitoring Database Information 
-	“States that share data with other state PDMPs,” (17 state programs); 
-	“States that share data with authorized users in other states,” (5 state programs); 
-	“States that share data with both,” (24 state programs).
Substances Monitored 
-	“Schedules II – IV,” (11 state programs);
-	“Schedules II – V,” (20 states programs); 
-	“Schedules II – IV and certain non-controlled substances,” (3 state programs);
-	“Schedules II – V and certain non-controlled substances,” (15 state programs).

Recent analyses of state PDMPs have identified significant variations in the structure and functioning of these programs, including the agency administering the program. As described by Pardo (2017), PDMPs differ in that they may be proactive (sending unsolicited reports to prescribers about suspicious prescribing patterns) or reactive, and may have different policies regarding funding, administrative review, and the management and retention of the gathered data ().
4.1	the Pennsylvania Prescription Drug Monitoring Program
Pennsylvania’s PDMP was established in 1972, and was one of the first programs in the United States (). Formerly administered by the Office of the Attorney General, the program is currently administered by the Pennsylvania Department of Health. Pennsylvania General Assembly Act 191 of 2014 established the current program structure and processes 
().
Based upon the NAMSL’s 2016 report and literature by the Pennsylvania Department of Health (2017), Pennsylvania’s Prescription Drug Monitoring Program has the following characteristics:
-	Schedule II through Schedule V controlled substances are monitored;
-	All Schedule II – V dispensed prescriptions must be reported to the system by the close of the next business day;
-	The PDMP Clearinghouse accepts data seven days per week;
-	The program permits prescribers to delegate access to the program; 
-	Dispensers and prescribers (and their delegates) have “real-time” access to program data;
-	Beginning on 1/1/2017, all licensed prescribers who “distribute, dispense or administer a controlled substance in the Commonwealth of Pennsylvania are required to register with the program”; and
-	Required querying of the PA PDMP in some instances:
Pennsylvania currently shares PDMP data with 15 other states and the District of Columbia ().
4.2	Impact of Prescription Drug Monitoring Programs
PDMP use (both mandated and non-mandated) has been associated with a number of positive outcomes. Analyses of data from numerous states such as Florida, Kentucky, and Ohio have found that increased PDMP use resulted in a decrease in total numbers of opioid prescriptions written by providers (; ; ). Decreases in overdose deaths and admissions to SUD treatment have also been associated with the implementation of state PDMPs and PDMP use (). A national survey conducted in 2016 found that PDMP implementation was associated with a reduction in opioid-related overdose deaths in the subsequent year by about one per 100,000 on average ().
PDMPs have also shown utility in the identification and treatment of individuals with or at risk for opioid-related substance use disorder. Research has found an increased likelihood of providers screening patients after querying a PDMP, and an increase in patient referrals made to substance use disorder treatment and pain management specialists by providers using PDMPs (). PDMPs also have utility in providing and managing treatment, by allowing providers to examine prescription histories for undisclosed prescriptions and potential negative drug-drug interactions such as in cases of opioids and benzodiazepines being taken concurrently.
Pardo (2017) evaluated state PDMPs on criteria including monitoring of more than Schedule II drugs, proactive (required) monitoring, degree of law enforcement access to the program, and reporting frequency, as well as the presence/absence of a requirement for prescribers to review PDMP before prescribing, sharing of data with other states, requirements for evaluation of the program, existence of oversight, data retention policies, and funding issues. Pardo’s finding was that the strength of a PDMP is significantly related to opioid pain reliever-related deaths. As the author notes, there are multiple other significant factors that need to be considered in further analyses related to PDMP effectiveness, including the availability of naloxone access programs, the nature of state pain clinic regulations, and Good Samaritan Laws. Most significantly, Pardo’s findings indicated that states with medical marijuana dispensaries reported fewer opioid deaths than those without dispensaries (). The importance and life-saving reality of the strength of a state’s prescription monitoring program is a critically important finding of Pardo’s research. This strongly supports recent efforts to standardize the characteristics of PDMPs across states. In an earlier study of the impact of prescription monitoring programs Reifler, et al. (2012) evaluated data from Poison Center and Opioid Treatment surveillance databases (2003 to 2009), and found that presence of a state PDMP was associated with both decreased poison center exposures and less opioid treatment admissions, on average ().
4.3	Limitations on Monitoring programs in their current state
In their current state, prescription drug monitoring programs face numerous limitations barring providers from using them to their greatest potential in providing treatment. Variability in state legislation regarding instances of mandated PDMP use, data collection intervals, substances monitored, and legally authorized users can hinder the ability of prescribers, dispensers, and their delegates to access important information, and access information in a timely manner. 
Furthermore, data sharing agreements between states, or more importantly, the lack of data sharing between states poses a serious challenge in adequately and efficiently reviewing prescription histories of patients, particularly when data between neighboring states is not shared. Such is the case of Pennsylvania and Maryland, where the current data sharing agreement only allows for Maryland provider access to the Pennsylvania PDMP. A well-documented tactic of drug diversion is the crossing of state lines to obtain prescriptions, and the lack of data sharing a data sharing agreement, such as in the case of Pennsylvania’s inability to access Maryland PDMP records, poses a challenge in the ability of PA dispensers to determine legitimacy of prescriptions and assess for possible diversion. Table 4 below shows a breakdown of PDMP data accessibility by provider type for the states that PA currently shares data with.














 Source: (, )

Another important limitation on the use of PDMPs is the difficulty of effectively integrating their use into clinical workflow, as they are a separate database with log-in credentials, although funding is now available to support PDMP integration into electronical medical records. Common barriers to PDMP use by providers include the amount of time needed to access the system, difficulty of navigating the database and searching for patient records, lack of knowledge for interpreting data contained within records, lack of training to conduct evidence-based screening and assess for possible substance use disorder. 
5.0 	recommendations for improving prescription monitoring programs and preventing substance use disorder
Many potential improvements to prescription drug monitoring have been proposed.  A comprehensive review of the research evidence for potential best practices was conducted by Clark, et al. (2012) and summarized in a report prepared for The Pew Charitable Trusts. Clark, et al. found research evidence for the following “potential best practices”:
“1. Collect data on all schedules of controlled substances    					2. Institute serialized prescription forms								3. Conduct epidemiological analyses 								4. Provide continuous online access to automated reports 					5. Send unsolicited reports and alerts        							6. Conduct promotional campaigns 									7. Improve data timeliness and access 								8. Conduct user education”
The authors identified a total of 35 potential best practices with varying degrees of support and indicated that additional assessment of the effectiveness of promising practices is needed. Some examples of these additional practices include the following: “Adopt a uniform and latest ASAP reporting standard, collect data on nonscheduled drugs implicated in abuse; reduce data collection interval; move toward real time data collection; enable access to data by appropriate users; encourage innovative applications; enact and implement interstate data sharing among PDMPs; and collaborate with other agencies and organizations” ().
5.1	Public Health Implications of a National Level Prescription Monitoring Database
The development of a national level prescription drug monitoring program could have a significant impact on mitigating the ongoing opioid crisis in the United States. Beyond improving accessibility of patient prescription history, a national level prescription drug monitoring database could have many potential advantages over current state-run models. The standardization of factors such as authorized users, regulations regarding instances of mandated PDMP use, data collection intervals, and substances reported would address many of the challenges providers face currently in efficiently and effectively extracting and analyzing important data from PDMP systems.
Perhaps the best method of implementing the national level database would be to arrange for data sharing with current state-run databases instead. This would allow providers to easily access prescription data across state lines and allow states to retain their individual databases to oversee and enforce. Retaining state databases would also allow for the collection of additional data in instances where state legislation imposes stricter requirements than federal law regarding use of the national database.  The creation and maintenance of such a database would likely require the cooperation of various state and federal agencies, such as agencies currently overseeing state level prescription drug monitoring databases, the United States Drug Enforcement Agency, and the United States Department of Health and Human Services.
Currently only 22 states with PDMPs have mandates requiring prescribers to query the database prior to prescribing an opioid or other controlled substance (). As evidenced by prior research, states with mandated use saw decreases in the rates of prescriptions written and overdose deaths occurring, as well as in increase in the number of referrals made to substance use treatment and pain management specialists. Mandated use of a national PDMP database could lead to the further reductions in opioid prescription and overdose death rates nationally, and significantly impact the incidence of new opioid-related substance use disorders by removing large volumes of prescriptions opioids from communities.
5.1.1	Potential Impact on Infectious Disease Transmission
Multiple health consequences of Opioid Use Disorder have been identified. Negative health consequences associated with opioid use include bloodborne infections acquired through needle sharing such as HCV and HIV, sexually transmitted infections, infections of the skin, and tuberculosis  ADDIN EN.CITE (; ; ), and a mortality rate of 1.5%–2% per year (). In a review of the literature on the impact of opioid drug abuse upon the immune system, Roy, et al. (2011) concluded that, “All opioids, especially morphine, are known to alter or suppress the functionality of the various cell types of both innate and adaptive immunity, and that “the body of evidence in support of opioid immunosuppressive qualities is growing.” The authors cite suppression of pro-inflammatory responses and suppression of pro-inflammatory cytokine secretion as among the actions of morphine upon the immune system  ADDIN EN.CITE (). 
Improvement of current PDMPs or creation of a national level PDMP also has the potential to impact the transmission of infectious diseases. It is well documented that needle sharing during injection drug use poses a significant risk for the transmission of bloodborne pathogens such as HIV and HCV. Non-injection drug use has been associated with increased risk of transmission of infectious diseases as a result of risky behavior engaged in while under the influence of drugs or while seeking drugs such as unprotected sex. As evidenced by prior studies, implementation of state PDMPs had an impact on reducing the number of accessible opioids through reduced numbers of prescriptions (; ; ). Greater provider utilization of a PDMP database (state or national) when prescribing and tapering opioid drugs, and when screening patients could result in earlier identification of patients at risk for developing a substance use disorder and earlier intervention in cases of opioid misuse. This could prevent progression from prescription drug misuse to injection drug use in these patients, eliminating the potential for risky behaviors such as needle sharing, therefore prevent the transmission of HIV and HCV. 
However, it is simply not enough to prevent new cases from occurring. A possible unintended consequence of enforcing stricter legislation regarding PDMP use and opioid prescribing is that patients already struggling with prescription misuse and/or illicit drug use may rely more heavily on illicit drug use to meet their needs. This could potentially add to the burden on our criminal justice system by resulting in increased drug-related arrests and incarcerations. Thus, any stricter legislation surrounding accessibility of opioid dugs would also warrant improvement in the support services available to these individuals, e.g. greater funding for needle exchange programs and specialty treatment centers. Also important is improving outpatient treatment of substance use, as not every individual who uses opioids and other substances has the time or resources to commit to an inpatient treatment program.  
Wang et al. (2011) reported that HIV and HCV are the most likely cause of morbidity and mortality among injection drug users. The study also found opioids to have immunocompromising effects, enhancing HIV replication in vitro. The authors concluded that opioid abuse likely facilitates HIV and HCV disease progression  ADDIN EN.CITE (). Reductions in HIV transmission in turn could lead to further decrease in transmission of infectious diseases by decreasing the likelihood of transmission of tuberculosis, pneumonia, and other highly infectious “opportunistic infections” that can occur as a result of immunosuppression. It is estimated that 11% of tuberculosis cases globally are comorbid with HIV infection.
5.1.2	 Recommendations for Improving Prescription Drug Monitoring Program Use and Substance Use Disorder Treatment
While the development of a national level prescription drug monitoring database may be a possibility in the future, many of the challenges faced by current state-run programs can be addressed through education and training. Aside from training for navigating their state PDMP database, healthcare providers may benefit from further education and training on prescribing of opioids to different populations, opioid tapering practices, SBIRT training (Screening, Brief Intervention, and Referral to Treatment for SUD), non-opioid and non-pharmacological pain management therapies, and reducing stigma towards individuals who use opioids and other substances non-medically. Emphasis must also be given to treating substance use like a chronic illness, requiring careful attention and persistence to achieve sustained, long-term management of the condition. Both SAMSHA and ASAM (the American Society of Addiction Medicine) have expressed support of this model for treating substance use. Beyond the development of educational programs for healthcare providers who are already practicing, colleges and universities should evaluate their current curriculums and seek to improve opioid education for students preparing for medical professions. 
Hospitals and clinics could implement several measures to improve prevention and treatment of SUD such as stricter prescribing protocols, tapering protocols, and screening/referral protocols. Additionally, many electronic medical record companies like EPIC have begun to support the integration of state PDMP databases into their system, thus solving accessibility issues. This has helped improve clinical workflow related to PDMP use by automatically retrieving patient data and eliminating the need for providers to manually log into databases to conduct searches. Further improving this software to recognize warning signs such as multiple opioid prescriptions or filling of prescriptions across state lines could also aid in preventing and treating individuals with substance use.
Legislation should be enacted to improve data sharing across states and standardize certain characteristics of PDMPs such as specific substances monitored, data collection intervals, and accessibility of patient records to healthcare providers of different disciplines. This would resolve many of the issues currently faced by providers when using PDMPs, thus improving the clinical utility of state PDMP data to support decision making.
Lastly, additional technological options must be explored to improving prescribing, dispensing, and tracking of opioids. Funding should be allocated for developing services and methods by which single-doses of opioids could be dispensed to patients. An example could be a program similar to “meals on wheels” where home care service agencies or visiting nurses deliver the prescriptions at a set time each day. 
Prescription vending machines placed in secure healthcare setting like hospitals and pharmacies could also be an option. Patients receiving opioid therapy could receive a “prescription card” and a pin number (similar to a debit card) to use at the vending machine. The card could be programmed to dispense only the prescribed dose at the stated intervals, regardless of it the patient attempts to visit multiple vending machines. The machines could also be equipped with a screen to show information about the dispensed prescription (side effects, adverse drug interactions, etc.) and a call button for video-chatting a healthcare provider if counseling regarding medication use is needed. Tracking data from the vending machine regarding time/date/location of each dispensation could be recorded into the PDMP database, and if excess or early attempts are made to obtain prescriptions.
Such programs could improve medication adherence and reduce misuse/diversion by minimizing the volume of opioids accessible (dispensing one dose at a time) and including an element of human interaction with each dosing.  
5.1.3	Conclusions
While the implementation of state-run prescription drug monitoring programs has a had noticeable impact on lowering the rates of opioid prescribing and overdose deaths, it is clear that further actions are needed to truly curtail the ongoing opioid crisis. In addition to enacting legislation surrounding prescription drug monitoring programs to improve data collection and accessibility across states, it is important to also increase funding and accessibility of specialty drug treatment programs, which might see an increase in uptake as a result of improved screening of patients. Connecting more patients with substance use treatment programs could not only improve their physical health and wellbeing by focusing on rehabilitation, but also help these individuals avoid legal repercussions associated with drug use such as being sentenced to prison or being institutionalized. 
APPENDIX: U.S. DRUG ENFORCEMENT ADMINISTRATION DEFINITIONS OF DRUG SCHEDULES
Schedule I – “Drugs, substances, or chemicals defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.”
Schedule II – “Drugs with a high potential for abuse, with use potentially leading to severe psychological or physical dependence. These drugs are also considered dangerous. Some examples of Schedule II drugs are: Combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin.”
Schedule III – “Drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are: Products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, and testosterone.”
Schedule IV – “Drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol.”
Schedule V – “Drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes. Some examples of Schedule V drugs are: cough preparations with less than 200 milligrams of codeine or per 100 milliliters (Robitussin AC), Lomotil, Motofen, Lyrica, Parepectolin.” 
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